Bulgarian experience in the treatment with tyrosine-kinase inhibitor Imatinib mesylate (Glivec®) as a second-line therapy in patients with chronic myelogenous leukemia. Results after 18 months of treatment
DIFFERENTIATION POTENTIAL OF MESENCHYMAL STEM CELLS ISOLATED FROM THE WALL FROM HUMAN UMBILICAL VEIN
CHARACTERIZATION OF HUMAN MESENCHYMAL STEM CELLS ISOLATED FROM ADIPOSE TISSUE
Effects of smoking on body composition and fat distribution in a Bulgarian Population
ALLERGIC CONTACT DERMATITIS TO PARA-PHENYLENE DIAMINE
OPEN VERSUS LAPAROSCOPIC RADICAL PROSTATECTOMY
Chemotherapy in six family members with multiple echinococcosis
Union of bulgarian medical specialists
All rights reserved
e-mail: ubulms@gmail.com
telephone 0897 07 18 68
